{"id":62528,"date":"2026-06-09T15:42:29","date_gmt":"2026-06-09T06:42:29","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/4881-20260609-01_wp_basic\/"},"modified":"2026-07-12T11:23:06","modified_gmt":"2026-07-12T02:23:06","slug":"4881-20260609-01_wp_basic","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-4881\/ir\/4881-20260609-01_wp_basic\/","title":{"rendered":"Notice of Partnership Agreement for the Development of Transdermal Absorption Formulations of Antibody-Induced Peptides"},"content":{"rendered":"","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4881","jir_company_name":"FanPep Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-06-09","jir_source_link":"[Placeholder]","jir_short_summary":"FanPep entered into a joint research agreement with artience Co., Ltd. and Toyo Chemical Co., Ltd. for the development of transdermal delivery formulations of antibody-inducing peptides. FanPep will conduct efficacy and safety evaluations in animal studies, bearing the costs. There is no change to the R&D expense forecast for the fiscal year ending December 2026.","jir_summary":"### Section Heading\nThis release announces the signing of a joint research agreement with the Artience Group to strengthen collaboration. The development of transdermal delivery formulations of antibody-inducing peptides aims to have FanPep conduct efficacy and safety evaluations in animal studies, while Toyo Chemical conducts consideration of transdermal formulation. FanPep bears the research costs, and there is no change to the R&D expense forecast for the fiscal year ending December 2026.\n\n### Section 2 Heading\nThis collaboration aims to advance the next-generation formulation technology of low-invasiveness transdermal delivery systems, and is strategically important for investors as it strengthens the long-term R&D pipeline and market deployment. Specific timelines and performance metrics are not disclosed in this release, but progress updates, additional funding allocations, and milestone announcements are anticipated.","jir_financial_highlights":"Whether there is any change to the R&D expense forecast: Unknown","jir_category":"Partnerships & M&As","jir_hashtags":"#FanPep, #JointResearch, #TransdermalDelivery","jir_key_figures":"Partner: artience Co., Ltd., Toyo Chemical Co., Ltd.\nJoint research content: Development of transdermal delivery formulations for antibody-inducing peptides\nCost bearing: FanPep bears the costs related to the assigned tasks\nFiscal year ending December 2026: No change to the R&D expense forecast","jir_meta_title":"\u3010FanPep\u3011Notice of Joint Research Agreement | June 9, 2026","jir_meta_description":"FanPep enters into a joint research agreement with artience Co., Ltd. and Toyo Chemical Co., Ltd. for the development of transdermal delivery formulations of antibody-inducing peptides. Costs borne by FanPep; no change to the 2026 R&D expense forecast.","jir_og_title":"\u3010FanPep\u3011Notice of Joint Research Agreement","jir_og_description":"FanPep announces a joint research agreement with the Artience Group and Toyo Chemical to accelerate the development of transdermal delivery formulations, with FanPep bearing the costs and no change to the 2026 fiscal year forecast.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60650,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-62528","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notice of Partnership Agreement for the Development of Transdermal Absorption Formulations of Antibody-Induced Peptides - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4881\/ir\/4881-20260609-01_wp_basic\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4881\/ir\/4881-20260609-01_wp_basic\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4881\/ir\/4881-20260609-01_wp_basic\/\",\"name\":\"Notice of Partnership Agreement for the Development of Transdermal Absorption Formulations of Antibody-Induced Peptides - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-06-09T06:42:29+00:00\",\"dateModified\":\"2026-07-12T02:23:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4881\/ir\/4881-20260609-01_wp_basic\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4881\/ir\/4881-20260609-01_wp_basic\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4881\/ir\/4881-20260609-01_wp_basic\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Notice of Partnership Agreement for the Development of Transdermal Absorption Formulations of Antibody-Induced Peptides\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Notice of Partnership Agreement for the Development of Transdermal Absorption Formulations of Antibody-Induced Peptides - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4881\/ir\/4881-20260609-01_wp_basic\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4881\/ir\/4881-20260609-01_wp_basic\/","url":"https:\/\/japanir.jp\/en\/company\/company-4881\/ir\/4881-20260609-01_wp_basic\/","name":"Notice of Partnership Agreement for the Development of Transdermal Absorption Formulations of Antibody-Induced Peptides - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-06-09T06:42:29+00:00","dateModified":"2026-07-12T02:23:06+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4881\/ir\/4881-20260609-01_wp_basic\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4881\/ir\/4881-20260609-01_wp_basic\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4881\/ir\/4881-20260609-01_wp_basic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Notice of Partnership Agreement for the Development of Transdermal Absorption Formulations of Antibody-Induced Peptides"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"60650","title":"(\u682a)\u30d5\u30a1\u30f3\u30da\u30c3\u30d7","ticker":"4881"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/62528","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=62528"}],"version-history":[{"count":1,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/62528\/revisions"}],"predecessor-version":[{"id":78852,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/62528\/revisions\/78852"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=62528"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=62528"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=62528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}